

# Hemolytic-Uremic

[View the current Hemolytic-Uremic InDepth page on BioPortfolio.com \(PDF\)](#)

(<http://www.bioportfolio.com/indepth/Hemolytic-Uremic.html>) - Regularly Updated.

## Recent Publications on Hemolytic-Uremic:



- [Predictors of complications in therapeutic plasma exchange.](#)  
*Plasma exchange (PE) is used for blood purification to modulate proteins...*6th November, 2009  
Department of Medicine, Nephrology and Rheumatology,- J Clin Apher. 2009 Nov 3. ([DOI Direct Link](#))
- [Etiology and outcome of acute renal failure in pregnancy.](#)  
*Objective: To determine the etiology and outcome of Acute Renal Failure...*6th November, 2009  
Department of Nephrology, Jinnah Postgraduate Medical Centre, Karachi.- J Coll Physicians Surg Pak. 2009 Nov;19(11):714-7. ([DOI Direct Link](#))
- [Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead either to altered secretion or altered function of factor I.](#)  
*The complement system is regulated by inhibitors such as factor I (FI), a...*31st October, 2009  
Department of Laboratory Medicine, Medical Protein Chemistry, Malmo- Eur J Immunol. 2009 Oct 28. ([DOI Direct Link](#))
- [Atypical hemolytic-uremic syndrome.](#)  
*Kidney transplant in patients with atypical hemolytic uremic syndrome...*30th October, 2009  
Clinical Research Center for Rare Diseases Aldo e Cele Dacco, Mario Negri- N Engl J Med. 2009 Oct 22;361(17):1676-87. ([DOI Direct Link](#))
- [Severe atypical HUS caused by CFH S1191L-case presentation and review of treatment options.](#)  
*Atypical hemolytic uremic syndrome (aHUS) has been associated with...*27th October, 2009  
Division of Nephrology, The Hospital for Sick Children, 555 University- Pediatr Nephrol. 2009 Oct 24. ([DOI Direct Link](#))
- [Maintenance of Kidney Function Following Treatment With Eculizumab and Discontinuation of Plasma Exchange After a Third Kidney Transplant for Atypical Hemolytic Uremic Syndrome Associated With a CFH Mutation.](#)  
*Kidney transplant in patients with atypical hemolytic uremic syndrome...*27th October, 2009  
Paediatric Nephrology, Emma Children's Hospital/Academic Medical Centre,- Am J Kidney Dis. 2009 Oct 24. ([DOI Direct Link](#))
- [Recommendations for diagnosis of shiga toxin--producing Escherichia coli infections by clinical laboratories.](#)  
*Shiga toxin--producing Escherichia coli (STEC) are a leading cause of...*21st October, 2009  
Division of Foodborne, Bacterial, and Mycotic Diseases, National Center- MMWR Recomm Rep. 2009 Oct 16;58(RR-12):1-14.
- [Performance comparison of a fliC\(h7\) real-time PCR assay with an H7 latex agglutination test for confirmation of the H type of Escherichia coli O157:H7.](#)

*Escherichia coli* O157:H7 is a foodborne pathogen that causes hemorrhagic...17th October, 2009  
U.S. Department of Agriculture, Food Safety and Inspection Service,- J Food Prot. 2009  
Oct;72(10):2195-7.

- [\[Hamburger consumption patterns and exposure assessment for verocytotoxigenic Escherichia coli \(VTEC\): simulation model\]](#)  
*A quantitative risk assessment was developed for verocytotoxigenic...*17th October, 2009  
Consejo Nacional de Investigaciones Cientificas y Tecnicas, Departamento- Rev Argent Microbiol.  
2009 Jun-Sep;41(3):168-76.
- [Hemolytic-uremic syndrome in Switzerland: a nationwide surveillance 1997-2003.](#)  
*Hemolytic-uremic syndrome (HUS) is a leading cause of acute renal failure...*16th October, 2009  
University Children's Hospital UKBB, Roemergasse, 8, CH4058, Basel,- Eur J Pediatr. 2009 Oct 15. ([DOI Direct Link](#))
- [Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection, foodborne diseases active surveillance network sites, 2000-2006.](#)  
*BACKGROUND: Hemolytic uremic syndrome (HUS) is a life-threatening illness...*16th October, 2009  
Enteric Diseases Epidemiology Branch, National Center for Zoonotic,- Clin Infect Dis. 2009 Nov  
15;49(10):1480-5. ([DOI Direct Link](#))
- [Concurrent occurrence of membranous desquamation in Escherichia coli O157:H7 hemolytic uremic syndrome.](#)  
*BACKGROUND: Hemolytic uremic syndrome (HUS) is a life-threatening illness...*15th October, 2009  
- Clin Nephrol. 2009 Oct;72(4):328-30.
- [Safety and Pharmacokinetics of Urtoxazumab, a Humanized Monoclonal Antibody Against Shiga-Like Toxin 2 in Healthy Adults and Pediatric STEC- Infected Patients.](#)  
*Shiga-like toxin-producing Escherichia coli (STEC) infection causes...*14th October, 2009  
Hospital de Ninos "Dr. Ricardo Gutierrez" Buenos Aires, Argentina;- Antimicrob Agents Chemother.  
2009 Oct 12. ([DOI Direct Link](#))
- [Streptococcus Pneumoniae infection and hemolytic uremic syndrome.](#)  
*Shiga-like toxin-producing Escherichia coli (STEC) infection causes...*13th October, 2009  
- Nefrologia. 2009 Oct;29(5):496-497. doi: ([DOI Direct Link](#))
- [Alternative Pathway of Complement in Children with Diarrhea-Associated Hemolytic Uremic Syndrome.](#)  
*BACKGROUND AND OBJECTIVES: Diarrhea-associated hemolytic uremic syndrome...*13th October, 2009  
Division of Nephrology, University of Colorado, Denver School of Medicine,- Clin J Am Soc Nephrol.  
2009 Oct 9. ([DOI Direct Link](#))

## BioNews Results for Hemolytic-Uremic

- [Alexion Pharmaceuticals to Present Soliris Data at Annual ASH Meeting](#)  
*TradingMarkets: Nov 13 2009 5:28AM Matching: hemolytic uremic*
- [Researchers to Present Additional Data on Soliris \(eculizumab\) for the Treatment of Patients With PNH at the A](#)  
*Pharma Live: Nov 12 2009 12:03AM Matching: hemolytic uremic*
- [Researchers To Present Additional Data On Soliris\(R\) \(eculizumab\) For The Treatment Of Patients With PNH At Th](#)  
*Medical News Today: Nov 12 2009 6:19AM Matching: hemolytic uremic*
- [Alexion Pharmaceuticals Inc. \(ALXN\) Release: Researchers to Present Additional Data on Soliris\(R\) \(eculizumab\)](#)  
*BioSpace: Nov 11 2009 7:45PM Matching: hemolytic uremic*
- [Researchers to Present Additional Data on Soliris \(eculizumab\) for the Treatment of Patients With PNH](#)

[at the](#)

*Freshnews.com: Nov 11 2009 1:49AM Matching: hemolytic uremic*

- [Researchers to Present Additional Data on Soliris \(eculizumab\) for the Treatment of Patients With PNH at the A](#)

*NewsBlaze: Nov 11 2009 12:13AM Matching: hemolytic uremic*

- [Researchers to Present Additional Data on Soliris\(R\) \(eculizumab\) for the Treatment of Patients With PNH at the ASH Annual Meeting](#)

*Individual.com: Nov 11 2009 12:05AM Matching: hemolytic uremic*

- [Medical Progress: Atypical Hemolytic-Uremic Syndrome](#)

*New England Journal of Medicine: Oct 22 2009 1:23PM Matching: hemolytic uremic*

## Hemolytic-Uremic Patents:



- 7399613- [Sialic acid nucleotide sugars](#)
- 7465707- [Methods of treatment with TR10 polypeptides](#)
- 7468419- [Cyclosporin derivatives for the treatment of immune disorders](#)
- 7476384- [Death domain containing receptor 4 antibody and methods](#)
- 7479504- [Edg receptor agonists](#)
- 7482013- [Albumin fusion proteins](#)
- 7482147- [Ubiquitin protease](#)
- 7485308- [26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206, and 8843 molecules and uses therefor](#)
- 7491550- [Diagnostics and therapeutics for diseases associated with Neuromedin U2 receptor \(NMU2\)](#)
- 7498027- [Methods of treatment using human tumor necrosis factor receptor TR17 antibodies](#)
- 7498130- [Method of reducing viral load](#)
- 7465548- [Methods of screening for potential therapeutics for diseases associated with G-protein coupled receptor HM74a](#)
- 7459531- [50 Human secreted proteins](#)
- 7452538- [Death domain containing receptor 4 antibodies and methods](#)
- 7411051- [Antibodies to HDPPA04 polypeptide](#)
- 7411054- [25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor](#)
- 7417069- [Halogenated triptolide derivatives as immunomodulators and anticancer agents](#)
- 7425424- [Kinases and uses thereof](#)
- 7429646- [Antibodies to human tumor necrosis factor receptor-like 2](#)
- 7435824- [Prodrugs of potassium channel inhibitors](#)
- 7435828- [Thiazolidin-4-one derivatives](#)
- 7439043- [Galactosyl nucleotide sugars](#)
- 7439053- [Transformed Shigella](#)
- 7439347- [Hepatitis C virus non-structural NS3/4A fusion gene](#)
- 7507413- [Albumin fusion proteins](#)
- 7507414- [Albumin fusion proteins](#)
- 7566812- [Transgenic mouse models of hepatitis C virus \(HCV\) and identification of HCV therapeutics](#)
- 7569384- [Albumin fusion proteins](#)

- 7582654- [Heterocyclo inhibitors of potassium channel function](#)
- 7585860- [Substituted oxazolidinones and their use in the field of blood coagulation](#)
- 7592010- [Albumin fusion proteins](#)
- 7592339- [Substituted oxazolidinones and their use in the field of blood coagulation](#)
- 7604797- [Compositions and methods for treating burns](#)
- 7605171- [\(3,4-disubstituted\)propanoic carboxylates as S1P \(Edg\) receptor agonists](#)
- 7611879- [27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor](#)
- 7611893- [Metal-binding therapeutic peptides](#)
- 7560436- [Methods of treating gastrointestinal inflammation](#)
- 7553931- [Complement depletion using recombinant human C3-derivatives](#)
- 7553490- [Vaccines against Escherichia coli O157 infection](#)
- 7507730- [Substituted pyrazolo\[1,5-a\]pyrimidines as potassium channel activators](#)
- 7507839- [Therapeutic ion channel blocking agents and methods of use thereof](#)
- 7511017- [Methods of treatment with TNFR5](#)
- 7517522- [ADAMTS13 genes and proteins and variants and therapeutic compositions and methods utilizing the same](#)
- 7517890- [GTPase inhibitors and methods of use](#)
- 7521424- [Albumin fusion proteins](#)
- 7528239- [Receptor that binds trail](#)
- 7531315- [Method for detecting a host receptor for pathogenic bacteria](#)
- 7534428- [Antibodies to tumor necrosis factor receptors 6.alpha. and 6.beta.](#)
- 7541362- [Heterocyclic dihydropyrimidine compounds](#)
- 7612080- [GTPase inhibitors and use thereof for controlling platelet hyperactivity](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

